1-8 of 8
Kathryn Kolibaba, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Real-World Assessment of Hepatic Dysfunction Among Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Receiving First-Line (1L) Tyrosine Kinase Inhibitors (TKIs) in the United States

Kathryn Kolibaba, MD, Jie Zhou, PhD, Scott Justin Keating, MS, Jamyia Clark, PhD MPH, John Brokars, MS, Arianna Kee, Ronda Copher, PhD, Brian Stwalley, PharmD BCGP, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-141086
Published: 2020
Journal Articles

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Ian W. Flinn, MD PhD, David Andorsky, MD PhD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn Kolibaba, MD, Habte A. Yimer, MD, John M. Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Daniel Dingfeng Jiang, MD PhD, John C. Pesko, PhD, Tamas Vizkelety, MD, Simon Sharmokh, MPH, PharmD, Jeff P Sharman, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-137406
Published: 2020
Journal Articles

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial

Kathryn Kolibaba, MD, John M. Burke, MD, Heather D. Brooks, MD BS, BA, Daruka Mahadevan, MD PhD, Jason Melear, MD, Charles M. Farber, MD PhD, Suzanne R. Fanning, DO, Marshall T. Schreeder, MD, Ralph V. Boccia, MD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Jeff P. Sharman, MD
Journal: Blood
Blood (2015) 126 (23): 3980.
https://doi.org/10.1182/blood.V126.23.3980.3980
Published: 2015
Journal Articles

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

John P. Leonard, MD, Kathryn Kolibaba, MD, James A. Reeves, MD, Anil Tulpule, MD, Ian W. Flinn, MD PhD, Tatjana Kolevska, MD, Robert Robles, MD, Christopher Flowers, MD, Robert Collins, MD, Nicholas J. DiBella, MD, Steven W. Papish, MD, Parameswaran Venugopal, MD, Andrew Horodner, MD, Amir Tabatabai, MD, Julio Hajdenberg, MD, George Mulligan, PhD, Rachel Neuwirth, PhD, Kaveri Suryanarayan, Dixie-Lee Esseltine, MD, Sven de Vos, MD PhD
Journal: Blood
Blood (2015) 126 (23): 811.
https://doi.org/10.1182/blood.V126.23.811.811
Published: 2015
Journal Articles

CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response

Michael R. Savona, MD, Kathryn Kolibaba, MD, Paul Conkling, MD, Edwin C. Kingsley, MD, Carlos Becerra, MD, John Morris, MD, Robert M. Rifkin, MD, Eric Laille, MS, Amy Kellerman, BA, Stacey M. Ukrainskyj, BSN,RN, Qian Dong, MS, Barry S. Skikne, MD
Journal: Blood
Blood (2014) 124 (21): 4638.
https://doi.org/10.1182/blood.V124.21.4638.4638
Published: 2014
Journal Articles

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Franck Morschhauser, MD PhD, Ian Flinn, Ranjana H Advani, MD, Catherine S. Diefenbach, MD, Kathryn Kolibaba, MD, Oliver W. Press, MD PhD, Laurie H Sehn, MD MPH, Andy I Chen, MDPhD, Gilles Salles, MD PhD, Herve Tilly, MD, Bruce D. Cheson, MD, Sarit Assouline, MD MSc, Martin Dreyling, Anton Hagenbeek, MD PhD, Pier Luigi Zinzani, MD, Sreeni Yalamanchili, BSPharm, Dan Lu, PhD, Cheryl Jones, PhD, Surai Jones, PhD, Yu-Waye Chu, Jeff P. Sharman, MD
Journal: Blood
Blood (2014) 124 (21): 4457.
https://doi.org/10.1182/blood.V124.21.4457.4457
Published: 2014
Journal Articles

Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

John M. Burke, MD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Richard E. White, PhD, MPH, MBE, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, Ian W. Flinn, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 155.
https://doi.org/10.1182/blood.V120.21.155.155
Published: 2012
Journal Articles

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

Ian W. Flinn, MD, PhD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, John M. Burke, MD
Journal: Blood
Blood (2012) 120 (21): 902.
https://doi.org/10.1182/blood.V120.21.902.902
Published: 2012